BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hemophilia Alliance - ECPv6.3.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hemophilia Alliance
X-ORIGINAL-URL:https://hemoalliance.org
X-WR-CALDESC:Events for Hemophilia Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
TZID:America/Phoenix
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20270101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260722T130000
DTEND;TZID=America/New_York:20260722T140000
DTSTAMP:20260831T183316
CREATED:20260707T123846Z
LAST-MODIFIED:20260707T124404Z
UID:73269-1784725200-1784728800@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - An Update on Takeda’s Transformation\, Supply Status\, and Hemophilia A Treatments
DESCRIPTION:Date: Wednesday\, July 22nd\, 2026\nTime: 1:00pm – 2:00pm ET \n \n  \n  \n  \n \n  \nWEBINAR TOPIC: \nAn Update on Takeda’s Transformation\, Supply Status\, and Hemophilia A Treatments \nOBJECTIVES: \n\nTo familiarize audiences with Takeda transformation update\nTo share reminder on the HEMOFIL® M & RECOMBINATE® supply status\nTo share HCP presentation focusing on the immunogenicity results of the ADYNOVATE phase 3 trial in previously untreated patients (PUPs) and attributes of ADVATE for previously treated patients (PTPs).\n\n\nAUDIENCE: \nAll HTC Staff \nSPEAKERS: \nDr. Jonathan Roberts is the Associate Medical Director and Associate Research Director at the Bleeding and Clotting Disorders Institute in Peoria\, IL. He also serves as an Associate Professor of Pediatrics and Medicine at the University of Illinois College of Medicine in Peoria\, IL. \nDr. Roberts’ research focuses on developing novel laboratory assays to improve the diagnosis of von Willebrand Disease (VWD) and enhancing individualized clinical management of hemophilia\, VWD\, and other rare bleeding disorders. He has received numerous young investigator research awards and has authored over 100 peer-reviewed research publications and abstracts. His work includes lead and senior author publications in prominent journals such as Blood\, the Journal of Thrombosis and Haemostasias\, and the New England Journal of Medicine. He has also secured grant funding from organizations such as the National Bleeding Disorders Foundation\, the World Federation of Hemophilia\, and the National Institutes of Health. \n  \nCarley Riehle has been with Takeda for nearly nine years and has built her career around supporting the bleeding disorder community. She began in the field\, calling on HTCs\, hospitals\, and chapters before leading a team of field members\, where she developed a deep appreciation for the strength and resilience of the community. She later transitioned to Takeda’s Payer Team\, where she focused on creating and protecting access for patients on Takeda therapies. Most recently\, Carley was promoted to National Director of Specialty Pharmacy\, where she partners with national specialty pharmacies and the Hemophilia Alliance to strengthen Takeda’s relationships\, support their members\, and ultimately improve access for patients. She is passionate about building trusted partnerships and advancing meaningful support for the bleeding disorder community. \n  \n  \nNatalie Wu\, Head of Takeda’s US Hematology and Transplant Franchise is biopharmaceutical leader with over 25 years of diverse US and Global experience across Rare Diseases\, Oncology\, Diabetes\, and Neuroscience. Natalie is passionate about building deep connections with the patient communities we serve and the healthcare and advocacy teams who work tirelessly to support patients in their quest for better health. She challenges the status quo to drive meaningful impact where unmet needs and heath inequities remain. \n  \n  \nNicole Loguidice\, MBA is Director\, Foundational Therapeutics Platform Access Operations at Takeda. With more than eight years of experience in patient access\, she has led operations across Hematology\, Rare Disease\, Endocrinology\, and Transplant programs. Nicole is passionate about developing patient-centered access solutions\, fostering cross-functional collaboration\, and advancing programs that support patients’ access to the therapies they need.
URL:https://hemoalliance.org/alliance-events/an-update-on-takedas-transformation-supply-status-and-hemophilia-a-treatments/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260730T140000
DTEND;TZID=America/New_York:20260730T150000
DTSTAMP:20260831T183316
CREATED:20260707T205936Z
LAST-MODIFIED:20260707T205946Z
UID:73336-1785420000-1785423600@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Presents - A Webinar on Planning for Medicaid Work Requirements
DESCRIPTION:
URL:https://hemoalliance.org/alliance-events/a-webinar-on-planning-for-medicaid-work-requirements/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260826T130000
DTEND;TZID=America/New_York:20260826T140000
DTSTAMP:20260831T183316
CREATED:20260811T194603Z
LAST-MODIFIED:20260811T194603Z
UID:73448-1787749200-1787752800@hemoalliance.org
SUMMARY:🟥 Member Webinar : New HANS PBM Agreement Opportunities
DESCRIPTION:
URL:https://hemoalliance.org/alliance-events/member-webinar-new-hans-pbm-agreement-opportunities/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260923T130000
DTEND;TZID=America/New_York:20260923T140000
DTSTAMP:20260831T183316
CREATED:20260828T162902Z
LAST-MODIFIED:20260831T212519Z
UID:73534-1790168400-1790172000@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From Novo Nordisk - Preapproval Information Exchange: Denecimig for the treatment of hemophilia A
DESCRIPTION:Date: Wednesday\, September 23rd\, 2026\nTime: 1:00pm – 2:00pm ET \n \n \nWEBINAR TOPIC:\nPreapproval Information Exchange: Denecimig for the treatment of hemophilia A \nOBJECTIVES:\nDenecimig is a novel FVIIIa mimetic agent currently under investigation for the treatment of hemophilia A (congenital FVIII deficiency) with or without FVIII inhibitors. Denecimig has not been approved for any indication by any regulatory authority. This webinar will offer healthcare decision-makers an overview of the burden of disease in patients with hemophilia A\, a detailed introduction to denecimig\, its delivery (dosing and administration)\, and a summary of its clinical trial program. Denecimig is an investigational agent\, and its efficacy and safety have not been established. \n\nAUDIENCE:\nAll HTC Staff \nSPEAKER:\nCraig Schmidt\, PharmD\nMedical Accounts Associate Director\nNovo Nordisk Medical Affairs \nBefore joining Novo Nordisk in 2019\, Craig had been in the Community Pharmacy and Managed Care settings for 13 years and held various roles and leadership positions. Of note\, Craig was the Pharmacy Director of a Regional Health Plan that served over a million Medicaid\, Medicare\, and Commercially insured patients within the New York Metro area. \nCraig currently serves as a Medical Accounts Director for Novo Nordisk\, a global healthcare company with over 100 years of innovation and leadership in diabetes\, obesity\, and rare disease care. Craig is responsible for providing scientific support to payers\, specialty pharmacies\, and other stakeholders that advance the care for patients living with rare diseases. \nCraig earned his Doctor of Pharmacy from St. John’s University\, and is currently based out of Queens\, NY.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-novo-nordisk-preapproval-information-exchange-denecimig-for-the-treatment-of-hemophilia-a/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260927T183000
DTEND;TZID=America/New_York:20260929T173000
DTSTAMP:20260831T183316
CREATED:20250604T143303Z
LAST-MODIFIED:20260611T204255Z
UID:70983-1790533800-1790703000@hemoalliance.org
SUMMARY:🟥 Member Event : 2026 Fall Members Meeting & Hill Day
DESCRIPTION:Date: September 27 – 29\, 2026\nLocation: Washington\, DC \nPlease note: this button will redirect you to Cvent\, the Alliance’s NEW management registration platform. \n \n  \n  \n  \nPlease contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.
URL:https://hemoalliance.org/alliance-events/member-event-2026-fall-members-meeting-hill-day/
CATEGORIES:Members Only
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Phoenix:20270124T183000
DTEND;TZID=America/Phoenix:20270126T140000
DTSTAMP:20260831T183316
CREATED:20260810T124715Z
LAST-MODIFIED:20260810T124749Z
UID:73430-1800815400-1800972000@hemoalliance.org
SUMMARY:🟥 Member Event : 2027 MPBA Meeting
DESCRIPTION:Date: January 24 – 26\, 2027\nLocation: Salt Lake City\, UT \nPlease note: this button will redirect you to Cvent\, the Alliance’s NEW management registration platform. \n \n  \n  \nPlease contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.
URL:https://hemoalliance.org/alliance-events/member-event-2027-mpba-meeting/
CATEGORIES:Members Only
END:VEVENT
END:VCALENDAR